With Nasdaq delisting threat, IMV drops 3rd of staff in refocus on lead oncology asset
https://www.fiercebiotech.com/biotech/nasdag-delisting-looming-imv-drops-third-staff-refocus-lead-oncology-asset
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.